Diplomat Pharmacy (DPLO) Misses Q2 EPS by 6c; Lowers EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts DPLO Hot Sheet
Join SI Premium – FREE
Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.17, $0.06 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.42 billion.
GUIDANCE:
Diplomat Pharmacy maintains FY2018 revenue of $5.5-5.9 billion, versus the consensus of $5.67 billion. Diluted EPS between $(0.15) and $0.01, versus the previous range of $0.06 and $0.17
For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
- Tecnoglass (TGLS) Tops Q3 EPS by 2c ; Offers Guidance
- Portillo's Inc. (PTLO) Tops Q3 EPS by 3c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
